The major strength of our study is that it expands the knowledge on targeting CCL2 to prevent BPD and simultaneously refutes the concerns arising from the diverse outcomes of targeting the CCL2-CCR2 axis in the hyperoxia rodent models as detailed in the introduction. The gene discussed is CCR2; the disease is bronchopulmonary dysplasia.